Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086500 · ClinicalTrials.gov registry record · Phase 3
Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)
A Phase 3 study of Traumatic Hemorrhage, sponsored by Jason Sperry.
- Completed
- Registry status
- Phase 3
- Development phase
- 903
- Enrollment target
- 1
- Study location
NCT02086500 is a Phase 3 study of Traumatic Hemorrhage that has completed, run by Jason Sperry. The registered enrollment target is 903 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02086500, a Phase 3 study of Traumatic Hemorrhage, has completed, sponsored by Jason Sperry.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 903 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if 1 gram of prehospital tranexamic acid given during emergency medical transport to a level 1 trauma center in patients at risk of hemorrhage is associated with lower 30 day mortality.
Conditions Studied
Interventions
- DRUG Tranexamic Acid
- OTHER Saline control
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 903 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02086500
The ClinicalTrials.gov registry entry for NCT02086500 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 903 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jason Sperry, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Traumatic Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT02086500 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02086500 about?
NCT02086500 is a clinical study titled "Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)". The purpose of this study is to determine if 1 gram of prehospital tranexamic acid given during emergency medical transport to a level 1 trauma center in patients at risk of hemorrhage is associated with lower 30 day mortality.
What is the current status of trial NCT02086500?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 903 participants. The study started on 2015-07. Estimated completion is 2019-11.
What conditions does trial NCT02086500 study?
This clinical trial studies the following conditions: Traumatic Hemorrhage.
What interventions are being tested in trial NCT02086500?
The interventions under investigation include: Tranexamic Acid (DRUG), Saline control (OTHER).
Who is sponsoring clinical trial NCT02086500?
This trial is sponsored by Jason Sperry, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02086500 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.